Same-Day PET/CT Scheduling With Renal Impairment
A 68-year-old man is scheduled for an FDG PET/CT to evaluate a solitary pulmonary nodule. His most recent eGFR is 38 mL/min/1.73 m2 (drawn 3 weeks ago). He also has a documented allergy to iodinated contrast (hives and wheezing after a prior CT). He arrives at 08:00 and has been fasting since midnight, but his point-of-care glucose is 212 mg/dL. The technologist has 16 mCi of FDG on hand in a multidose vial, and the next patient is scheduled at 09:30 for a thyroid uptake scan. The ordering physician is in clinic and reachable by phone.
1. What should the technologist do first about the elevated glucose, and why does it matter for FDG PET/CT?
Read the worked answer
First action: contact the ordering physician before injecting.
- FDG is a glucose analog and competes with endogenous glucose for GLUT transporters and hexokinase. A glucose of 212 mg/dL produces high background uptake in muscle, liver, and bowel and can suppress tumor uptake - potentially a false-negative for a solitary pulmonary nodule, which is exactly the question being asked.
- Common practice is to reschedule or treat when glucose is markedly elevated (many protocols use a threshold around 150-200 mg/dL, though institutional policies vary). The technologist should not unilaterally cancel or inject; the physician decides whether to reschedule, treat and recheck, or proceed with documented acknowledgement of the limitation.
- If the study proceeds, document the glucose value and the physician's decision, since interpretation will be constrained. If rescheduled, the dose can be reallocated.
2. The CT portion of the PET/CT is ordered for attenuation correction and lesion localization only, without IV contrast. How does the contrast allergy and eGFR affect the plan?
Read the worked answer
Neither should block a non-contrast, low-dose CT.
- Attenuation-correction CT uses very low mAs and no IV contrast; iodinated contrast is not required. The documented contrast allergy is therefore not a contraindication for this acquisition. It would matter only if a diagnostic contrast-enhanced CT were requested, in which case premedication and physician discussion would be needed.
- eGFR 38 mL/min/1.73 m2 is relevant to iodinated contrast (contrast-induced nephropathy risk) but not to non-contrast CT or to FDG. FDG is cleared renally but is not nephrotoxic, and no dose adjustment is standard for PET.
- The technologist should confirm the protocol with the physician and document that the study is non-contrast, so the allergy and renal function do not inappropriately delay the exam.
3. How should the technologist manage the FDG supply and the 09:30 thyroid uptake patient?
Read the worked answer
Triage the dose and protect the other study.
- A thyroid uptake scan uses I-123 (or I-131) and is unaffected by FDG; the two are different radionuclides and different rooms/equipment. The main constraint is staff time and camera/uptake-probe availability, not cross-contamination of radiopharmaceuticals.
- If the PET patient is rescheduled, the 16 mCi FDG can be used for another scheduled PET patient or decayed; it should not be injected into the thyroid patient.
- If the PET proceeds, ensure the 09:30 patient is not delayed: the FDG uptake period (~60 min) can overlap with the thyroid uptake count if staffing allows. Communicate with the physician and scheduler, and document the glucose, the decision, and any reallocation of the dose.